Literature DB >> 28828581

Optimizing tumor immune response through combination of radiation and immunotherapy.

Alissar El Chediak1, Ali Shamseddine2, Larry Bodgi3, Jean-Pierre Obeid4, Fady Geara3, Youssef H Zeidan3.   

Abstract

Radiation therapy and immunotherapy are two highly evolving modalities for the treatment of solid tumors. Immunotherapeutic drugs can either stimulate the immune system via immunogenic pathways or target co-inhibitory checkpoints. An augmented tumor cell recognition by host immune cells can be achieved post-irradiation, as irradiated tissues can release chemical signals which are sensed by the immune system resulting in its activation. Different strategies combining both treatment modalities were tested in order to achieve a better therapeutic response and longer tumor control. Both regimens act synergistically to one another with complimentary mechanisms. In this review, we explore the scientific basis behind such a combination, starting initially with a brief historical overview behind utilizing radiation and immunotherapies for solid tumors, followed by the different types of these two modalities, and the biological concept behind their synergistic effect. We also shed light on the common side effects and toxicities associated with radiation and immunotherapy. Finally, we discuss previous clinical trials tackling this multimodality combination and highlight future ongoing research.

Entities:  

Keywords:  Abscopal; Immunotherapy; Radiation; SBRT

Mesh:

Year:  2017        PMID: 28828581     DOI: 10.1007/s12032-017-1025-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  109 in total

1.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

3.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 5.  Radiation and Immune Checkpoint Blockade: From Bench to Clinic.

Authors:  Jacob E Shabason; Andy J Minn
Journal:  Semin Radiat Oncol       Date:  2017-03-16       Impact factor: 5.934

6.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

7.  Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction.

Authors:  C M Roberts; E Foulcher; J J Zaunders; D H Bryant; J Freund; D Cairns; R Penny; G W Morgan; S N Breit
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

8.  Approaches to the prevention and management of radiation colitis.

Authors:  Mohammed A Qadeer; John J Vargo
Journal:  Curr Gastroenterol Rep       Date:  2008-10

Review 9.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

10.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

View more
  7 in total

Review 1.  Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies.

Authors:  Ignacio Morales-Orue; Rodolfo Chicas-Sett; Pedro C Lara
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-22

2.  Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy.

Authors:  Meng-Xi Chen; Yue-Ming Liu; Yang Li; Xuan Yang; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

Review 3.  Cancer immunotherapy: broadening the scope of targetable tumours.

Authors:  Jitske van den Bulk; Els Me Verdegaal; Noel Fcc de Miranda
Journal:  Open Biol       Date:  2018-06       Impact factor: 6.411

4.  The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Yuqi Chen; Chengzhi Cai; Yanying Li
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

Review 5.  Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application.

Authors:  Jinfeng Shi; Jiaxin Li; Ziyi Xu; Liang Chen; Ruifeng Luo; Chen Zhang; Fei Gao; Jinming Zhang; Chaomei Fu
Journal:  Front Pharmacol       Date:  2020-11-18       Impact factor: 5.810

6.  The Potentiation of Radiosensitization by Concomitant Treatment With Radiation Therapy and a PDL-1 Inhibitor in Cutaneous Squamous Cell Carcinoma.

Authors:  Celine A Fadel; Shivang U Danak; Jaymin Jhaveri; Misty D Caudell
Journal:  Adv Radiat Oncol       Date:  2022-07-08

7.  Radiation Dose Escalation is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance Local and Distant Antitumor Effect in Murine Osteosarcoma.

Authors:  Wataru Takenaka; Yutaka Takahashi; Keisuke Tamari; Kazumasa Minami; Shohei Katsuki; Yuji Seo; Fumiaki Isohashi; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.